CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
Plain-language summary
This Phase 2 trial is testing ATLCAR.CD30 T cells, Bendamustine, and other medications for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. It is available at 2 US locations.
Who can join (key eligibility)
- Age 18 Years to 99 Years years
- Lymphoma came back or did not respond to prior treatment
- May require specific number of prior treatments
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
ATLCAR.CD30 T cells (BIOLOGICAL): Autologous T Lymphocyte Chimeric Antigen Receptor cells targeted against the CD30 antigen at dose of 2 × 10\^8 CAR-T/m\^2 with a maximum dose of 5 × 10\^8 CAR-T cells | Bendamustine (DRUG): 70 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first cell infusion | Fludarabine (DRUG): 30 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first and second cell infusion | Cyclophosphamide (DRUG): 300 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to second cell infusion and 2-14 days prior to the first cell infusion for subjects who have previously had hypersensitivity to bendamustine
- Drugs / treatments
- ATLCAR.CD30 T cells, Bendamustine, Fludarabine, Cyclophosphamide
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details